U
TBRA

UBS’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

UBS’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$12K Buy
1,146
+1,021
+817% +$20.2K ﹤0.01% 8666
2014
Q2 		$8K Sell
125
-4,479
-97% -$272K ﹤0.01% 9152
2014
Q1 		$519K Buy
4,604
+4,430
+2,546% +$311K ﹤0.01% 4188
2013
Q4 		$7K Buy
174
+124
+248% +$5.82K ﹤0.01% 9372
2013
Q3 		$3K Buy
+50
New +$2.62K ﹤0.01% 9845

Other funds holding TBRA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $150M AUM 32.35% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS's TBRA Position: Q3 2014 in Review

UBS increased its Tobira Therapeutics, Inc. Common Stock (TBRA) stake by 817% in Q3 2014, buying an estimated $20.2K and bringing the position to 1,146 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #8666.

UBS first reported a position in TBRA in Q3 2013 and has held it in 5 quarters since. The position peaked at $519K in Q1 2014. 47 funds tracked by Wall St. Rank hold TBRA as of Q3 2014.

  • UBS held 1,146 shares of Tobira Therapeutics, Inc. Common Stock worth $12K as of Q3 2014.
  • UBS bought 1,021 Tobira Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $20.2K.
  • Tobira Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8666 holding.
  • UBS first reported a position in Tobira Therapeutics, Inc. Common Stock in Q3 2013 and has held it in 5 quarters since.
  • UBS's Tobira Therapeutics, Inc. Common Stock position peaked at $519K in Q1 2014.
  • 47 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.